Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: Gastric cancer has a high mortality rate. Therapeutic management must be multidisciplinary to offer the patient the best, personalized strategy. Patients and methods: other regimens. The primary endpoints were pathological response rate, care continuity rate and survival outcomes. A total of 96 patients attending the Hospital "Policlinico San Matteo" in Pavia (Italy) between January 2012 and August 2022 were selected for the study. Results: =0.586). Conclusions: Despite the limitations, the results obtained were consistent with the medical literature and confirmed the effectiveness of the FLOT chemotherapy in real life. Nevertheless, some questions remain: the application in elderly patients, the addition of immunotherapy in patients with microsatellite instability or with high PD-L1 levels, comparison with chemoradiotherapy in junctional cancers and real cure rates. The FLOT regimen has revolutionized the treatment of resectable gastric cancer, but caution is needed before considering it an absolute standard of care.
Source: Drugs in Context
Authors: Francesco Serra, Federica Valerio, Paolo Pedrazzoli, Jacopo Viganò, Riccardo Caccialanza, Daniela Cicognini, Anna Pagani, Salvatore Corallo
Institutions: University of Pavia, Policlinico San Matteo Fondazione
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,901
OpenAlex ID: W4407524546